A more recent version of this regulatory record is available. This version is kept only as a historical record. Please see the Record history section for link to the most recent version.
List details
Basic info
Status | Intention |
---|---|
Submitter | Denmark |
Regulatory programme |
|
Further substance information | The information included on the SID of this UVCB substance originates from the REACH registration dissimination page. |
Classification
Proposed harmonised classification by the dossier submitter |
|
---|
Intention timeline
Date of intention | 2019-11-07 |
---|---|
Expected date of submission | 2020-03-01 |
Documents
Related substances
By adding any of the following substances to your watchlist, you would be monitoring this regulatory record and all possible new regulatory records related to that substance.
Related regulatory records
Record history
The following timeline shows when we detected changes of this regulatory record (the date might slightly differ from the date of the actual change). Additions between versions are hightlighted in green color, red color shows data removed between versions.
March 16, 2020
- Submitter email: mst@mst.dk
May 19, 2020
- Expected date of submission: 2020-03-01 → 2020-09-01
- Proposed harmonised classification by the dossier submitter: Muta. 2, H341
Aug. 21, 2020
- Expected date of submission: 2020-09-01 → 2020-10-01
- Further substance information: The information included on the SID of this UVCB substance originates from the REACH registration dissimination page.
Jan. 6, 2021
- Status: Intention → Submitted
- Submitted for accordance check: 2020-12-21
May 11, 2021
- Proposed specific concentration limits by the dossier submitter: C => 0,001%
- Submitter email: mst@mst.dk → info@mst.dk
May 25, 2021
- Deadline for commenting: 2021-07-30
- Final submission date: 2021-05-05
- Hazard classes open for commenting: Skin sensitisation Germ cell mutagenicity
- Legal deadline for opinion adoption: 2022-11-04
- Status: Submitted → Consultation
- Start of consultation: 2021-05-31
May 28, 2021
- Deadline for commenting: 2021-07-30 → 2021-08-06
- Start of consultation: 2021-05-31 → 2021-06-07
- Status: Consultation → Submitted
June 7, 2021
- CLH report: https://echa.europa.eu/documents/10162/742d5fed-2ace-e798-5e89-1dea63692285
- Status: Submitted → Consultation
Oct. 8, 2021
- Comments received: https://echa.europa.eu/documents/10162/7eb9699b-b177-0abc-ee8e-3ec1cc81791e
- Status: Consultation → Opinion Development
April 26, 2022
- Date of opinion: 2022-03-18
- Status: Opinion Development → Opinion Adopted
July 13, 2022
- Background document: https://echa.europa.eu/documents/10162/ffbf9b2e-5d3c-59ff-475c-e1fc62e48a97
- Comments received: https://echa.europa.eu/documents/10162/7eb9699b-b177-0abc-ee8e-3ec1cc81791e → https://echa.europa.eu/documents/10162/e6556784-a659-7f7d-4b8e-795450036cbd
- RAC opinion: https://echa.europa.eu/documents/10162/af871a8f-f316-6705-6cc0-3ce76d1423b2
This version
Add the related substance to your watchlist to monitor this regulatory record.